iDexis Fights Ban on Semaglutide | Johannesburg News

iDexis, a compounding pharmacy in South Africa, is facing another legal setback after the high court in Pretoria rejected its bid to overturn a ban on making semaglutide-based medicines — the key ingredient in Ozempic and Wegovy. The judge slammed their appeal as a “lengthy diatribe” and an abuse of process, saying they merely recycled arguments already dismissed. While the ruling is interim and tied to ongoing health investigations, it’s a major win for the Pharmaceutical Task Group, which champions public safety and regulatory integrity. iDexis vows to fight again at the Supreme Court of Appeal, though they’ve already halted production of semaglutide and tirzepatide following a May raid. For now, they’re operating only as a regular pharmacy, with health professionals urged not to stock recalled products — and compliance appears strong. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2310f8581041c971